miR-142在恶性实体瘤临床应用中的研究进展  

Progress in the clinical application of miR-142 in malignant solid tumors

作　　者：伍婷 莫靓 杨心治 游咏 WU Ting;MO Liang;YANG Xinzhi;YOU Yong(Research Laboratory of Translational Medicine,Hengyang Medical School,University of South China,Hunan Hengyang 421001,China;Department of Thoracic Surgery,the First Affiliated Hospital,Hengyang Medical School,University of South China,Hunan Hengyang 421001,China)

机构地区：[1]南华大学衡阳医学院转化医学研究室,湖南衡阳421001 [2]南华大学衡阳医学院附属第一医院胸外科,湖南衡阳421001

出　　处：《现代肿瘤医学》2024年第17期3360-3366,共7页Journal of Modern Oncology

基　　金：湖南省自然科学基金(编号:2021JJ30618,2022JJ50158);湖南省临床医疗技术创新引导项目(编号:2020SK51825)。

摘　　要：miR-142是一种进化上保守的非编码RNA(non-coding RNA,ncRNA)定位于17q22,与多种恶性实体瘤的发生发展密切相关。miR-142在乳腺癌、肺癌、肝癌、结直肠癌、胃癌、宫颈癌等多种恶性实体瘤中存在异常表达,参与恶性肿瘤细胞增殖和转移、细胞周期、自噬和化疗耐药等一系列生物学过程。该文基于现有文献,系统综述了miR-142在不同恶性实体瘤进展中的分子机制,为后续在恶性实体瘤中的临床应用研究提供新思索。miR-142 is an evolutionarily conserved non-coding RNA localized at 17q22 and is closely associated with the development of many malignant solid tumors.miR-142 is aberrantly expressed in many malignant solid tumors,including breast,lung,liver,colorectal,gastric and cervical cancers,and is involved in a series of biological processes such as malignant cell proliferation and metastasis,cell cycle,autophagy and chemotherapy resistance.In this paper,based on the existing literature,we systematically review the expression of these tumors.Based on the existing literature,this paper systematically reviews the molecular mechanisms of miR-142 in the progression of different malignant solid tumors and provides new ideas for subsequent clinical application studies in malignant solid tumors.

关 键 词：恶性实体瘤 miR-142 化疗耐药 自噬 治疗靶点 

分 类 号：R730[医药卫生—肿瘤]